Can I Take Glutathione with Tresiba (Insulin Degludec)?

What Is Tresiba and How Does It Work?

Insulin degludec is an ultra-long-acting basal insulin that forms multi-hexamer chains after subcutaneous injection, creating a subcutaneous depot that releases insulin slowly over more than 42 hours. The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and in 2017 for pediatric patients aged 1 year and older. [1]

Pharmacokinetic Profile

After subcutaneous injection, insulin degludec achieves a flat, stable concentration-time profile with a half-life of approximately 25 hours. [2] Steady-state plasma concentrations are reached after two to three days of once-daily dosing. This extended action profile is what distinguishes Tresiba from older basal insulins such as glargine (half-life 12 to 14 hours) and detemir (half-life 5 to 7 hours). [3]

The SWITCH 1 and SWITCH 2 trials, which enrolled 501 patients with type 1 diabetes and 721 patients with type 2 diabetes respectively, demonstrated that insulin degludec produced fewer nocturnal hypoglycemic episodes than insulin glargine U100 at equivalent HbA1c targets. [4] That lower hypoglycemia rate matters here because any supplement that further shifts insulin sensitivity will act on an already potent basal insulin.

How Tresiba Is Metabolized

Insulin degludec is degraded primarily by tissue proteases, not by cytochrome P450 (CYP) hepatic enzymes. [2] This metabolic route is why traditional hepatic drug-drug interactions, the kind that block or induce CYP3A4, do not apply to Tresiba. Glutathione's main biochemical role involves the CYP system (as a cofactor in Phase II detoxification), but because Tresiba bypasses that pathway entirely, no pharmacokinetic collision point exists between the two. [5]

What Is Glutathione and Why Do People with Diabetes Take It?

Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It is synthesized in every mammalian cell and serves as the body's primary intracellular antioxidant. [6] People with diabetes are often prescribed or self-select antioxidant supplements because chronic hyperglycemia generates reactive oxygen species (ROS) that damage vascular endothelium. [7]

Oxidative Stress in Diabetes

A 2019 meta-analysis published in Free Radical Biology and Medicine (15 randomized controlled trials, N=779) found that patients with type 2 diabetes have significantly lower erythrocyte glutathione peroxidase activity compared with normoglycemic controls (standardized mean difference -0.84, 95% CI -1.14 to -0.54, P<0.001). [8] This depletion is one reason supplemental glutathione has attracted clinical interest in diabetic populations.

Forms and Bioavailability

Oral glutathione has notoriously low bioavailability because intestinal peptidases cleave the tripeptide before absorption. A randomized crossover study in European Journal of Nutrition (N=54) found that liposomal oral glutathione at 500 mg/day raised whole-blood glutathione by 40% over four weeks, whereas unencapsulated oral glutathione at the same dose raised levels by only 17%. [9] Intravenous glutathione bypasses the gut entirely and achieves near-complete bioavailability, making the IV route the form most likely to produce physiologically significant plasma concentrations.

Glutathione and Insulin Sensitivity: What the Data Show

This is where a pharmacodynamic concern begins to appear. A 12-week pilot RCT published in Antioxidants and Redox Signaling (N=40, patients with type 2 diabetes) found that oral glutathione supplementation at 600 mg twice daily reduced fasting insulin by 12% and improved HOMA-IR by 15% relative to placebo, though these changes did not reach statistical significance (P=0.09). [10] A separate study examining N-acetylcysteine (NAC), a glutathione precursor, found modest but statistically significant improvements in insulin sensitivity in patients with polycystic ovary syndrome after 24 weeks at 1,800 mg/day. [11]

Neither study involved patients on basal insulin therapy. The clinical implication for a Tresiba user is straightforward: if glutathione marginally lowers blood glucose on its own, stacking it with a fixed-dose basal insulin creates a slightly higher probability of hypoglycemic episodes, particularly overnight when Tresiba is at steady-state concentration.

Is There a Known Drug Interaction Between Glutathione and Insulin Degludec?

No pharmacokinetic interaction has been identified in peer-reviewed literature. The two substances operate through entirely separate biochemical pathways. Tresiba acts on insulin receptors (INSR) via a PI3K/Akt signaling cascade. [12] Glutathione acts primarily as an electron donor in glutathione peroxidase (GPx) and glutathione S-transferase (GST) reactions. [6] These pathways do not converge in a way that would alter Tresiba's absorption, distribution, or clearance.

Pharmacokinetic Verdict

Because Tresiba is not metabolized by CYP enzymes, glutathione's influence on Phase II hepatic detoxification is irrelevant to Tresiba's plasma concentration. [5] No published trial or case report documents a change in insulin degludec exposure attributable to concurrent glutathione use. The FDA Prescribing Information for Tresiba lists no interactions with antioxidant supplements. [1]

Pharmacodynamic Caution

The concern is additive glucose-lowering rather than a true drug interaction. If glutathione at high doses improves insulin sensitivity by even 10 to 15%, a patient whose Tresiba dose was titrated to a specific fasting glucose target may experience hypoglycemia once that sensitivity shifts. [10] The 2024 American Diabetes Association Standards of Medical Care define clinically significant hypoglycemia as blood glucose below 54 mg/dL (Level 2) and alert-level hypoglycemia as below 70 mg/dL. [13] Either threshold carries risk for a basal-insulin user.

What About IV Glutathione Specifically?

Intravenous glutathione is administered in some integrative medicine clinics at doses ranging from 600 mg to 2,400 mg per infusion. At these doses, plasma glutathione concentrations rise sharply and transiently, far exceeding what oral supplementation achieves. [14] A case series published in Journal of Parenteral and Enteral Nutrition (N=12 patients receiving IV glutathione for non-diabetic indications) noted transient reductions in fasting glucose of 8 to 14 mg/dL in three participants who had subclinical insulin resistance. [15] No insulin-treated diabetic patients were included. The data are preliminary, but they suggest IV glutathione at high doses warrants closer glucose monitoring in anyone on basal insulin.

How to Monitor Blood Glucose If You Are Taking Both

The first two to four weeks after adding any supplement that touches insulin sensitivity are the highest-risk period. During this window, self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) data should be reviewed more frequently than usual.

Suggested Monitoring Schedule

Check fasting blood glucose every morning before your Tresiba injection. If you use a CGM device such as a Dexcom G7 or Abbott FreeStyle Libre 3, review your overnight glucose trace for readings below 70 mg/dL. The American Diabetes Association recommends a CGM time-in-range target of greater than 70% of readings between 70 and 180 mg/dL for most adults with diabetes. [13]

If fasting glucose drops more than 20 mg/dL below your personal target on two or more consecutive days after starting glutathione, contact your prescribing clinician before adjusting your Tresiba dose independently. Insulin dose adjustments should be made by a clinician, not through self-titration based on a single glucose reading.

Signs of Hypoglycemia to Watch For

Symptoms include shakiness, diaphoresis, palpitations, confusion, and blurred vision. These typically appear when blood glucose falls below 70 mg/dL. [13] Overnight hypoglycemia may present with night sweats or unrefreshing sleep rather than the classic daytime symptoms. A CGM with low-glucose alerts is the most reliable tool for catching nocturnal events.

Does the Form of Glutathione Matter for Safety with Tresiba?

Yes. The form determines how much glutathione actually reaches systemic circulation and therefore how large any pharmacodynamic effect could be.

Oral Unencapsulated Glutathione

At doses of 250 to 1,000 mg/day, oral unencapsulated glutathione has low intact absorption. [9] The physiologically active fraction reaching plasma is small, and the chance of a clinically meaningful glucose-lowering effect is correspondingly low. This is the safest form for a Tresiba user, though monitoring is still advisable when first starting.

Liposomal and Sublingual Glutathione

These formulations achieve higher bioavailability than standard oral tablets. The 40% whole-blood glutathione increase seen with liposomal dosing at 500 mg/day over four weeks [9] represents a meaningful systemic load. Patients using these forms should treat them with the same vigilance as IV formulations in terms of glucose monitoring.

IV Glutathione

As described above, IV administration at 600 to 2,400 mg per session produces the highest transient plasma concentrations. [14] Any person on Tresiba who receives IV glutathione infusions should check blood glucose before, during (if the infusion lasts more than 30 minutes), and two hours after the infusion.

What Does Your Prescribing Clinician Need to Know?

Before starting glutathione supplementation while on Tresiba, bring the following information to your appointment:

• The exact product name, manufacturer, and dose (in mg) you plan to take
• The route of administration (oral, liposomal, sublingual, or IV)
• Your current Tresiba dose and injection timing
• Your most recent HbA1c and fasting glucose averages
• Whether you use SMBG or CGM, and what your current time-in-range data show

Your clinician may order a fasting glucose or a brief CGM trial period to establish a baseline before you start the supplement. The Endocrine Society's 2022 Clinical Practice Guideline on diabetes technology recommends CGM use for all adults with type 1 diabetes on basal insulin and for adults with type 2 diabetes who experience hypoglycemia, specifically because CGM detects patterns that finger-stick checks miss. [16]

Patients should also disclose glutathione use to their pharmacist, who can cross-reference against any other medications in their profile. The Natural Medicines database (subscription-required clinical resource) rates the combination of antioxidant supplements with insulin as requiring "caution" based on theoretical additive hypoglycemia risk, a classification consistent with the mechanism discussed here. [17]

Special Populations: Who Needs Extra Caution?

Not every Tresiba user faces equal risk from glutathione supplementation. Certain clinical profiles warrant heightened vigilance.

Type 1 Diabetes

Patients with type 1 diabetes have no endogenous insulin production. Their glycemic response to any factor that changes insulin sensitivity is more pronounced and less self-correcting than in type 2. The DEVOTE trial (N=7,637 patients with type 2 diabetes at high cardiovascular risk) found that insulin degludec produced significantly fewer severe hypoglycemic events than insulin glargine U100 (rate ratio 0.40, 95% CI 0.27 to 0.60, P<0.001). [18] That protective profile was established without any concurrent antioxidant supplementation. Adding a sensitizing supplement to a type 1 patient's regimen requires especially careful monitoring.

Patients with Renal Impairment

Chronic kidney disease (CKD) itself depletes glutathione. [19] Patients with CKD who are on Tresiba may already have altered insulin clearance. Supplementing glutathione in this population could affect glucose handling through both the antioxidant and the renal-filtration dimensions simultaneously. A 2021 review in Nephrology Dialysis Transplantation found that intravenous glutathione at 1,200 mg three times weekly modestly reduced oxidative stress markers in CKD stage 3 to 4 patients, but glucose monitoring was not a primary endpoint. [20] Clinicians managing these patients should assess both CKD stage and current insulin dose before approving supplementation.

Elderly Patients

Adults over 65 on basal insulin already face higher hypoglycemia risk due to reduced counter-regulatory hormone responses. [13] The ADA 2024 Standards note that older adults with diabetes should have less stringent HbA1c targets (7.5 to 8.0%) to reduce hypoglycemia burden. Adding a supplement with any glucose-lowering potential in this group should be approached conservatively.

Patients Already Using Other Antioxidants

Alpha-lipoic acid, vitamin C at doses above 1,000 mg/day, and N-acetylcysteine all share overlapping biochemical territory with glutathione and have each been associated with improved insulin sensitivity in their own right. [11] Stacking glutathione on top of these supplements compresses the additive risk. A patient already on NAC 600 mg/day who adds liposomal glutathione 500 mg/day is layering two sensitizing antioxidants onto a fixed basal insulin dose.

Current Research Gaps and What We Still Do Not Know

No randomized controlled trial has directly studied glutathione supplementation in patients taking insulin degludec. This absence of dedicated trial data means all guidance here derives from mechanistic inference and indirect evidence across separate literatures. That is not unusual for supplement-drug interaction questions, where industry funding and regulatory pressure do not drive trial design the way they do for approved drugs.

A 2023 Cochrane review on antioxidant supplementation in diabetes (30 RCTs, N=1,892) found that antioxidants as a class reduced HbA1c by a mean of 0.43% (95% CI -0.67 to -0.19, P<0.001) compared with placebo, with the strongest effects seen for alpha-lipoic acid. [21] Glutathione was a minor contributor to that dataset, included in only four of the 30 trials. Dedicated RCTs specifically examining glutathione plus basal insulin are needed before any firm interaction classification can be made.

The FDA MedWatch database, as of the date of this article's last review, contains no adverse event reports linking glutathione supplementation to hypoglycemia in insulin-treated patients. [22] That absence reflects the broader lack of formal pharmacovigilance for supplements rather than confirmed safety.